Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
2211985-36-1
Molecular formula
Not available
Molecular weight
Not available
Drug class
Neonatal Fc receptor (FcRn) blockerfully human IgG1 monoclonal antibody
Mechanism of action
Binds FcRn and prevents recycling of IgG, increasing lysosomal degradation and lowering circulating IgG concentrations, including pathogenic autoantibodies.
Indications / reported uses
Treatment of generalized myasthenia gravis in adults and paediatric patients aged 12 years and older who are anti-AChR or anti-MuSK antibody positive
Treatment of warm autoimmune haemolytic anaemia in adults and paediatric patients aged 12 years and older currently or previously treated with corticosteroids under the US IMAAVY indication (2026 label update)
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Nipocalimab Environmental Risk Assessment (ERA) (the Nipocalimab ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.